Kronos Bio, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue
Operating expenses:
Research and development
General and administrative
Impairment of long-lived assets and restructuring
Total operating expenses
Loss from operations
Other income (expense), net:
Change in fair value of convertible notes payable
Interest expense
Interest income and other expense, net
Total other income (expense), net

Net loss
Other comprehensive income (loss):
Net unrealized gain (loss) on available-for-sale securities
Net comprehensive loss
Net loss per share, basic and diluted (in dollars per share)
Weighted-average shares of common stock, basic and diluted (in shares)
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)
Weighted-average shares of common stock, basic (in shares)
Weighted-average shares of common stock, diluted (in shares)

Comments